La cadena de opciones muestra datos clave de las opciones de acciones de Pliant Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Pliant Therapeutics..

Pliant Therapeutics (NASDAQ:PLRX) Bolsa, Cadena de Opciones

Pliant Therapeutics

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Pliant Therapeutics Inc

T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) has outperformed the market over the past 10 years by 13.19% on an annualized basis producing an average annual return of 24.51%. Currently, T-Mobile US has a market capitalization of $269.04 billion. 
Buying $1000 In TMUS: If an investor had bought $1000 of TMUS stock 10 years ago, it would be worth $9,240.64 today based on a price of $231.83 for TMUS at the time of writing.
<h3>T-Mobile US's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734132608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

TMUS

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 11.52% on an annualized basis producing an average annual return of 22.84%. Currently, Apollo Global Management has a market capitalization of $99.83 billion. 
Buying $100 In APO: If an investor had bought $100 of APO stock 10 years ago, it would be worth $801.95 today based on a price of $176.43 for APO at the time of writing.
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734131721_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) has outperformed the market over the past 10 years by 18.06% on an annualized basis producing an average annual return of 29.38%. Currently, MSCI has a market capitalization of $48.99 billion. 
Buying $100 In MSCI: If an investor had bought $100 of MSCI stock 10 years ago, it would be worth $1,331.98 today based on a price of $625.10 for MSCI at the time of writing.
<h3>MSCI's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734130821_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MSCI

Here's How Much $100 Invested In MSCI 10 Years Ago Would Be Worth Today

CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) announced today that its Board of Trustees declared a quarterly dividend of $0.52 per common share for the period ending December 31, 2024. The dividend is payable on January 16, 2025 to common shareholders of record on January 2, 2025.&nbsp;&nbsp;

Dividends

CUBE

CubeSmart Increases Quarterly Common Dividend From $0.51 To $0.52 Per Share

Insight Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 10.59%. Currently, Insight Enterprises has a market capitalization of $5.18 billion. 
Buying $100 In NSIT: If an investor had bought $100 of NSIT stock 20 years ago, it would be worth $753.63 today based on a price of $158.94 for NSIT at the time of writing.
<h3>Insight Enterprises's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734129012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NSIT

Here's How Much You Would Have Made Owning Insight Enterprises Stock In The Last 20 Years

CKPT

Trading Halt: Halted at 5:26:59 p.m. ET - Trading Halt: Halt News Pending

SPX Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) has outperformed the market over the past 5 years by 11.87% on an annualized basis producing an average annual return of 25.45%. Currently, SPX Techs has a market capitalization of $7.21 billion. 
Buying $1000 In SPXC: If an investor had bought $1000 of SPXC stock 5 years ago, it would be worth $3,074.32 today based on a price of $155.53 for SPXC at the time of writing.
<h3>SPX Techs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734128108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPXC

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Alpha Modus Holdings, Inc. ("Alpha Modus" or the "Company"), a technology company with a core focus on artificial intelligence in retail, is pleased to announce that the business combination between Insight Acquisition Corp. and Alpha Modus Corp. has closed, and Alpha Modus's common stock and warrants will begin trading on the Nasdaq Global Market under the ticker symbols "AMOD" and "AMODW", respectively, on Monday, December 16, 2024.
In connection with the closing of the business combination, the combined company consummated and issued a secured convertible promissory note to an investor, in exchange for net proceeds of approximately $2.6 million, which will be used primarily to cover transaction costs and for working capital. The structure of the financing does not include commitment or warrant shares and is structured with the potential for an additional $5 million capital infusion for working capital purposes in the future.

AMOD

INAQ

Alpha Modus And Insight Acquisition Corp Close Business Combination And Alpha Modus Will Begin Trading Under "AMOD" Ticker, December 16, 2024

NKTX

Nkarta 13G Filing Shows Citadel Advisors Reported A 5.4% Stake In The Co As Of December 6, 2024

Offerings

WATT

Energous Corp Files For Mixed Shelf Of Up To $80M

LKQ Corp Detects Unauthorized Access To It Systems In Canada; Canada Business Unit Operations Impacted For A Few Weeks Due To Cyber Incident; Business Unit In Canada Now Operating Near Full Capacity; Believes Cyber Incident Impacts Not Material To Financial Condition For FY

<figure class="table"> 
<table>
<tbody>
<tr>
<td> Termination of a Material Definitive Agreement</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
On January 7, 2022, Century Therapeutics, Inc. (the "Company") entered into a Research, Collaboration and License Agreement (the "Collaboration Agreement") with Bristol-Myers Squibb Company ("BMS") to collaborate on the research, development and commercialization of induced pluripotent stem cell derived, engineered natural killer cell and/or gamma delta T cell programs for hematologic malignancies.
&nbsp;
Following an internal corporate portfolio prioritization process, BMS notified the Company on December 12, 2024 that it would be terminating the Collaboration Agreement in its entirety without cause. The termination will be effective on March 12, 2025. The Company is encouraged by the scientific progress on the programs and will evaluate opportunities in acute myeloid leukemia and multiple myeloma in the context of the ongoing strategic review of Century's pre-clinical pipeline. Both parties will work together in accordance with the termination provisions of the Collaboration Agreement.

Biotech

Contracts

General

IPSC

Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma  In The Context Of The Ongoing Strategic Review Of Century's Pre-clinical Pipeline

Earnings

XCHG Q2 2024 EPS $(0.002) Down From $0.001 YoY; Revenue $9M Down From $12.20M  YoY

Insider Trades

Alaska Air Group CEO And President Benito Minicucci Sold 30,000 Shares At An Average Price Of $65.07/Share

TKO Group Files For Mixed Shelf; Size Not Disclosed

Amrep (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXR#NYSE">AXR</a>) reported quarterly earnings of $0.75 per share. This is a 257.14 percent increase over earnings of $0.21 per share from the same period last year. The company reported $11.91 million in sales this quarter. This is a 34.47 percent increase over sales of $8.85 million the same period last year.

Amrep Q2 EPS $0.75 Up From $0.21 YoY, Sales $11.91M Up From $8.85M YoY

What Happened: OpenAI has responded to Elon Musk's legal efforts to prevent its transition to a fully for-profit structure, accusing the billionaire of undermining the company after failing to gain control <a href="https://www.benzinga.com/topic/openai">during earlier negotiations.</a> 
In a recent blog post, OpenAI revealed that Musk had initially supported restructuring the organization into a for-profit entity in 2017 but abandoned the idea when his proposal to hold majority control was rejected. "[Musk] walked away and told us we would fail," OpenAI stated, <a href="https://www.cnbc.com/2024/12/13/openai-says-elon-musk-wanted-it-to-be-for-profit-in-2017.html">CNBC </a>reports.
The dispute stems from Musk's broader critique of OpenAI, which he co-founded, and its growing relationship with Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). Musk has filed for a court injunction, claiming the company's shift betrays its original nonprofit mission. 
Musk's complaints also allege that Microsoft benefits from restricted access to advanced AI models <a href="https://www.benzinga.com/24/12/42382569/elon-musk-asks-was-it-ever-not-a-lie-as-he-accuses-openai-of-selling-out-to-microsoft-and-betraying-its-founding-mission">while stifling competition.</a> He voiced concerns about monopolistic behavior in the industry, which have been central to his ongoing legal disputes with OpenAI and Microsoft.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42489039/feds-december-meeting-could-crush-rate-cut-optimism-for-2025">Fed&#8217;s December Meeting Could Crush Rate Cut Optimism For 2025</a>
OpenAI, however, maintains that the transformation aligns with its mission of advancing artificial intelligence responsibly, while remaining competitive in an evolving market.
Why It Matters: Musk's criticisms highlight growing tension within the AI industry as organizations navigate commercial pressures and ethical concerns. OpenAI has become a dominant force in generative AI, valued at $157 billion and attracting substantial investments, including $14 billion from Microsoft.
Musk, meanwhile, has positioned his own venture, xAI, as a rival, raising billions and launching its Grok chatbot. The unfolding legal battle underscores the high stakes in a sector expected to reach $1 trillion in revenue within a decade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42489019/teslas-76-post-trump-rally-bullish-run-or-signal-to-cash-out">Tesla&#8217;s 76% Post-Trump Rally: Bullish Run Or Signal To Cash Out?</a></li>
</ul>
Photo: Shutterstock

Legal

Tech

MSFT

TSLA

OpenAI Challenges Musk's Lawsuit, Reveals 2017 Profit Talks

Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) has outperformed the market over the past 5 years by 39.72% on an annualized basis producing an average annual return of 53.31%. Currently, Abercrombie &amp; Fitch has a market capitalization of $7.15 billion. 
Buying $1000 In ANF: If an investor had bought $1000 of ANF stock 5 years ago, it would be worth $8,484.24 today based on a price of $142.03 for ANF at the time of writing.
<h3>Abercrombie &amp; Fitch's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734126317_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Abercrombie & Fitch 5 Years Ago Would Be Worth This Much Today

Scale AI, a San Francisco-based <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence</a> startup with a $13.8 billion valuation and high-profile partnerships across the tech industry, is facing a class-action lawsuit alleging wage theft and worker misclassification.
The lawsuit, filed Tuesday in San Francisco Superior Court by former contractor Steve McKinney, names Scale AI and its top executives, including 27-year-old billionaire CEO Alexandr Wang, as defendants. 
McKinney alleges Scale built its success by exploiting workers, accusing the company of practices like unpaid labor, denied overtime and unfair reassignments. As such, the lawsuit seeks class-action certification, restitution, punitive damages and changes to Scale's worker classification model, <a href="https://www.sfgate.com/tech/article/sf-tech-startup-scale-ai-sued-wage-theft-19976761.php?sid=65d21e793be09a5bd409b575&amp;utm_source=newsletter&amp;utm_medium=email&amp;utm_term=briefing&amp;utm_campaign=sfgt%20%7C%20the%20daily&amp;stn=nf">according</a> to SFGate, which reported this on Friday.
"Scale AI is the sordid underbelly propping up the generative AI industry," the complaint states, describing the company's control over contractors as "Orwellian." It accuses Scale of monitoring contractors with tools that take periodic screenshots of their computer use, docking pay for tasks that exceed estimated time limits and reassigning workers to lower-paying projects. 
The lawsuit also claims Scale violated California's "ABC" test for independent contractors, asserting that workers like McKinney should be classified as employees.
Scale spokesperson Tom Channick responded to the allegations. "We do not comment on litigation but are committed to ensuring we are in full compliance with all applicable laws and regulations," he told SFGate in a statement, adding that contractors working for Scale enjoy flexible, supplemental income and earn significant sums.
<h1 class="wp-block-heading">Dark Side Of AI&#8217;s Rapid Growth</h1>
The lawsuit underscores the darker side of the AI industry's rapid growth, noting the disturbing and at times traumatic tasks contractors are sometimes assigned. McKinney's complaint alleges, for example, that workers are assigned to projects "that deal with obscene and distressing subject matter, where Taskers must provide responses to prompts regarding extremely disturbing topics." The document provides the example of "sexual intercourse with dead animals."
Channick countered the claims, stating that workers receive advanced notice about sensitive tasks, can opt out at any time and have access to wellness programs. However, McKinney's attorney, Glenn Danas, said in a news release quoted by SFGate that such tasks are traumatizing for workers. "If companies like Scale AI are not held accountable, humans will continue to be exploited to train this unregulated technology for profit," Danas said.
<h1 class="wp-block-heading">Scale&#8217;s Meteoric Rise</h1>
Scale AI, founded in 2016, positioned itself as a frontrunner in the AI&nbsp;industry,&nbsp;years before&nbsp;OpenAI's&nbsp;ChatGPT gained popularity. According to <a href="https://fortune.com/2024/05/21/scale-ai-funding-valuation-ceo-alexandr-wang-profitability/">Fortune</a>, Scale contractors annotated images for Cruise and Waymo, aiding autonomous vehicle tech and supplied data for OpenAI. With a $13.8 billion valuation, Scale partners with Meta Platforms, Microsoft, Nvidia and the Department of Defense.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42476730/peter-thiels-founders-fund-leads-600m-crusoe-investment-betting-big-on-ai-infrastructure">Peter Thiel Says, &#8216;The Biggest Risk With AI Is That We Don&#8217;t Go Big Enough&#8217; As His Founders Fund Leads $600 Million Crusoe Investment</a></li>
</ul>
Image generated with AI

NVDA

Wage Theft Allegations Target $13.8B Tech Giant Scale AI

The tech-heavy Nasdaq 100 index – as tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – extended its relentless climb this week, setting new record highs and nearing the 22,000-point milestone, fueled by strong investor optimism in the Magnificent Seven tech giants and the transformative <a href="https://www.benzinga.com/news/large-cap/24/12/42447567/magnificent-seven-tech-titans-hit-182-trillion-market-cap-alphabet-amazon-apple-meta-tesla-jointly-notch-all-time-highs">potential of artificial intelligence.</a>
Year-to-date, the index has posted a robust 30% gain, on track to outperform the S&amp;P 500 for the ninth time in the last decade.
Since the start of 2023, the Nasdaq 100 is on track to double, nearing a 100% gain &#8211; a performance last achieved in 2019-2020 with a 102% rise and previously hit during the dot-com boom of 1998-1999.
Notably, five out of the seven Magnificent Seven stocks— Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) — achieved fresh record highs this week. The combined market capitalization of the group exceeded $18 trillion, surpassing China's gross domestic product at the end of 2023.
Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) emerged as the week's standout performer, soaring after a strong quarterly earnings beat and delivering upbeat AI-driven guidance for the coming year. The rally propelled the chipmaker into the exclusive $1 trillion market-cap club, making it the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42488220/broadcom-hits-1-trillion-milestone-the-next-magnificent-tech-giant">eighth-largest publicly traded company.</a>
Inflation data released during the week raised some red flags. Consumer inflation rose 2.7% year-over-year in November, in line with expectations, but producer inflation jumped to 3% year-over-year, <a href="https://www.benzinga.com/news/treasuries/24/12/42460477/producer-inflation-rises-more-than-expected-to-3-in-november-cast-shadow-on-further-disinflation-progress">exceeding estimates of 2.6%.</a> This marked the sharpest increase since February 2023, raising concerns about potential cost pass-throughs to consumers.
Investors are fully pricing in a 25-basis-point interest rate cut at the Federal Reserve&#8217;s Dec. 18 meeting. Yet policymakers may signal fewer rate cuts for 2025 — potentially just three — while leaving open the possibility of a pause as early as January.
You may have missed&#8230; 
<h3 class="wp-block-heading">Trump Rings NYSE</h3>
President-elect Donald Trump rang the New York Stock Exchange opening bell on Thursday, expressing confidence in a strong U.S. economy. Trump was named TIME Person of the Year for the second time.
<h3 class="wp-block-heading">GM Robotaxi Exit</h3>
General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) plans to abandon its robotaxi ambitions, aiming to save $1 billion annually and potentially license Tesla&#8217;s Full Self-Driving technology, <a href="https://www.benzinga.com/markets/equities/24/12/42429325/robotaxi-exit-to-clear-the-way-for-gm-to-license-tesla-fsd-says-gary-black-move-will-save-the-mary-barra-led-company-1b-a-year">says analyst Gary Black.</a>
<h3 class="wp-block-heading">Google&#8217;s Quantum Leap</h3>
Alphabet's new Willow quantum chip showcases cutting-edge innovation. Analysts praise Google for advancing technology leadership, signaling potential breakthroughs in computing power <a href="https://www.benzinga.com/24/12/42447332/alphabets-quantum-willow-chip-wows-analyst-google-at-the-leading-edge-of-technology-innovation">and commercial applications.</a>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42489039/feds-december-meeting-could-crush-rate-cut-optimism-for-2025">Fed&#8217;s December Meeting Could Crush Rate Cut Optimism For 2025</a></li>
</ul>

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

AAPL

AMZN

AVGO

GOOGL

AI-Driven Rally Pushes Tech Stocks To Records, Broadcom Enters Trillion-Dollar Club, Inflation Data Flashes Warning Signal: This Week In The Markets

In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report). The company's sha...

Pliant Therapeutics (PLRX) Receives a Buy from TD Cowen

Pliant Therapeutics GAAP EPS of -$0.95

Needham analyst Joseph Stringer has maintained their bullish stance on PLRX stock, giving a Buy rating yesterday. Joseph Stringer's rating is based...

Positive Outlook on Pliant Therapeutics: Strategic Developments and Financial Stability Support Buy Rating

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), with a pri...

RBC Capital Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)

Oppenheimer analyst Jeff Jones maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report) today and set a price target of $45.00. The ...

Oppenheimer Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)

Pliant Therapeutics (PLRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C...

Positive Clinical Progress and Promising Data Support Buy Rating for Pliant Therapeutics

Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of ...

Buy Rating on Pliant Therapeutics Driven by Promising Bexotegrast Developments and Strategic Market Positioning

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of $43...

Promising Pipeline and Strong Financials Reinforce Buy Rating for Pliant Therapeutics

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q3 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to i...

Pliant Therapeutics Reports Increased Losses and Strategic Focus

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report) yesterday and set a price target o...

Positive Developments in Pliant Therapeutics' IPF Research Bolster Buy Rating

PLRX

Press Releases

Pliant Therapeutics to Participate in Upcoming Investor Events

Health Care

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

Management

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

Comments

Pliant Therapeutics

Pliant Therapeutics (PLRX) Opciones

Pliant Therapeutics (NASDAQ:PLRX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL